Tuesday Feb 17, 2026
Tuesday Feb 17, 2026
Monday, 16 February 2026 03:07 - - {{hitsCtrl.values.hits}}
Facility to produce isotopes for PET scans and cancer diagnostics
Commissioning scheduled for today
Access Engineering PLC will invest nearly $ 6.9 million in the establishment of a cyclotron-based radiopharmaceutical production facility in Sri Lanka under a build, operate and own (BOO) model.
Access Engineering holds a 60% equity stake in Access Medical Tracers Ltd., the entity undertaking the project.
A cyclotron-based radiopharmaceutical production facility is a specialised medical manufacturing centre that produces radioactive isotopes used in nuclear medicine. A cyclotron accelerates charged particles to generate short-lived radioactive isotopes, which are then processed into radiopharmaceuticals used primarily in Positron Emission Tomography (PET) scans and other diagnostic imaging procedures, particularly in oncology.
Given the short half-life of many isotopes used in PET imaging, local production is critical to ensure timely availability for hospitals and diagnostic centres. The facility will include the cyclotron unit, radiochemistry laboratories, quality control systems, and associated infrastructure required to produce and distribute radiopharmaceuticals safely.
Access Engineering said the cyclotron-based radiopharmaceutical production facility will be commissioned today (16).
The investment is part of Access Engineering’s diversification beyond its core engineering and construction operations into healthcare-related infrastructure.
The Access Engineering share price closed Friday up Rs. 2.40 at Rs. 72.50. It reported net assets of Rs. 37.61 a share as of end-December 2025.
During the nine months to end-December 2025 quarter, the Group reported a 38% year-on-year growth in revenue at Rs. 36 billion, with its automobile segment contributing Rs. 17 billion, civil engineering Rs. 13 billion, and construction materials production Rs. 5.7 billion, with after-tax profits up 15% to Rs. 4 billion.
